Initial viral response is the most powerful predictor of the emergence of YMDD mutant virus in chronic hepatitis B patients treated with lamivudine
Authors:
- 23 November 2007
- journal article
- Published by Wiley in Hepatology Research
- Vol. 38 (5) , 450-456
Abstract
Aim: Lamivudine (LAM) has been widely used to treat chronic hepatitis B (CHB) patients, but the emergence of a LAM‐resistant virus greatly limits its therapeutic efficacy. In this study, we tried to identify factors affecting the emergence of a LAM‐resistant virus in CHB patients treated with LAM.Methods: The subjects were 190 CHB patients in continuous LAM therapy (139 males, mean age 50 years, 87 HBeAg‐positive). The mean duration of follow‐up was 39 months (range 12–104). The initial viral response (IVR) was defined as HBV DNA < 4.0 logcopies/mL, and the initial biochemical response (IBR) as normalization of alanine aminotransferase (ALT) ( 6.5 logcopies/mL (P = 0.0044), HBeAg‐positivity (P = 0.0062), IBR (P = 0.01) and IVR (P < 0.0001). The cumulative emergence rates of LAM‐resistant virus in IVR‐positive and ‐negative patients were 4% and 41% at 1 year, and 41% and 79% at 3 years. In multivariate analysis, only IVR was an independent factor affecting the emergence of LAM‐resistant virus (P < 0.0001).Conclusion: IVR is a useful factor for predicting the emergence of LAM‐resistant virus in CHB patients treated with LAM. For IVR‐negative patients, therapeutic options other than LAM monotherapy should be used because of the high incidence of the emergence of LAM‐resistant virus.Keywords
This publication has 23 references indexed in Scilit:
- Two-Year Assessment of Entecavir Resistance in Lamivudine-Refractory Hepatitis B Virus Patients Reveals Different Clinical Outcomes Depending on the Resistance Substitutions PresentAntimicrobial Agents and Chemotherapy, 2007
- Long-term Therapy With Adefovir Dipivoxil for HBeAg-Negative Chronic Hepatitis B for up to 5 YearsGastroenterology, 2006
- Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis BJournal of Hepatology, 2005
- Body surface area is an independent factor contributing to the effects of lamivudine treatmentHepatology Research, 2005
- Severe acute exacerbation of liver disease may reduce or delay emergence of YMDD motif mutants in long‐term lamivudine therapy for hepatitis B e antigen‐positive chronic hepatitis BJournal of Medical Virology, 2004
- Clinical evaluation of the COBAS Amplicor HBV monitor test for measuring serum HBV DNA and comparison with the Quantiplex branched DNA signal amplification assay in TaiwanJournal of Clinical Pathology, 2004
- Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology, 2001
- Development of a new method for detecting a mutation in the gene encoding hepatitis B virus reverse transcriptase active site (YMDD motif)Hepatology Research, 2000
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998